Asia Pacific Peptide Therapeutics Market Size, Share & Industry Trends Analysis Report By Type (Innovative and Generic), By Route of Administration, By Synthesis Technology, By Type of Manufacturers, By Application, By Country and Growth Forecast, 2022 - 2028

The Asia Pacific Peptide Therapeutics Market is expected to witness market growth of 7.3% CAGR during the forecast period (2022-2028).

PEGylation, serum albumin binding, glycosylation, cyclization, and lipidation are some of the peptide modifications used to extend half-life. PEGylation is the covalent bonding of polyethylene glycol (PEG) chains to peptides, which helps to enhance molecular weight while also limiting enzymatic breakdown due to steric hindrance induced by the PEG. PEGylation has several advantages in pharmaceutical applications, including enhanced water solubility, high solution mobility, low toxicity, and low immunogenicity. This, however, is dependent on the connected PEG's molecular weight. PEGylation as a strategy to improve half-life has been proved numerous times.

Attaching glycosyl (carbohydrate) units to the peptide is another chemical alteration that aids in peptide distribution to target sites. Carbohydrates can be added to peptides to change their physiological characteristics and increase their bioavailability. Increased metabolic stability along with facilitated transport across cell membranes are two advantages of this approach, but one of the most appealing features is its potential to promote oral absorption. Because of limited absorption and quick breakdown and elimination, peptides have lower oral availability of less than 1-2%, making this technique appealing. N- and O-glycosylation, in which carbohydrates are connected to the peptide, occurs naturally, with N-glycosylation forming an amide bond through the amine group of an asparagine residue.

Lung cancer, China's top cause of cancer death, has seen a dramatic increase in incidence and mortality rates in recent years, with geographic and gender inequalities as a result of differences in socioeconomic and lifestyle growth. Smoking, air pollution, as well as occupational characteristics are all linked to lung cancer. However, lung cancer incidence and mortality could be reduced by behavioral interventions, such as smoking cessation and screening.

As per the National Library of Medicines, in 2017, cancer caused around 62.9 million disability-adjusted life years (DALYs) in China. The most significant contribution was made by lung cancer, which was followed by stomach cancer, liver cancer, and esophageal cancer. China's success in lowering liver and stomach malignancies has been witnessed. However, China still has a high rate of lung cancer and a growing rate of malignancies associated with a westernized lifestyle, such as colorectal cancer, whereas Japan and South Korea have both reduced their rates of colorectal cancer and lung cancer.

Furthermore, compared to Japan and South Korea, China has a lower age-standardized cancer occurrence but higher cancer death and DALY rates. Due to peptide therapy’s characteristics of being efficient in the treatment of cancer, the demand and adoption of this approach are increasing. Therefore, the growth of the regional market is flourishing.

The China market dominated the Asia Pacific Peptide Therapeutics Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $4,384.4 million by 2028. The Japan market is experiencing a CAGR of 6.6% during (2022-2028). Additionally, The India market is expected to exhibit a CAGR of 7.9% during (2022-2028).

Based on Type, the market is segmented into Innovative and Generic. Based on Route of Administration, the market is segmented into Parenteral Route, Pulmonary, Mucosal, Oral Route, and Others. Based on Synthesis Technology, the market is segmented into Liquid Phase Peptide Synthesis (LPPS), Solid Phase Peptide Synthesis (SPPS), and Hybrid Technology. Based on Type of Manufacturers, the market is segmented into In-house and Outsourced. Based on Application, the market is segmented into Metabolic, Cardiovascular Disorder, GIT & Renal, Antiinfection & Dermatology, Respiratory, Central Nervous System, Cancer, Pain, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eli Lilly And Company, AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Lonza Group AG, and Amgen, Inc.

Scope of the Study

Market Segments Covered in the Report:

By Type

• Innovative
• Generic

By Route of Administration

• Parenteral Route
• Pulmonary
• Mucosal
• Oral Route
• Others

By Synthesis Technology

• Liquid Phase Peptide Synthesis (LPPS)
• Solid Phase Peptide Synthesis (SPPS)
• Hybrid Technology

By Type of Manufacturers

• In-house
• Outsourced

By Application

• Metabolic
• Cardiovascular Disorder
• GIT & Renal
• Antiinfection & Dermatology
• Respiratory
• Central Nervous System
• Cancer
• Pain
• Others

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

Key Market Players

List of Companies Profiled in the Report:

• Eli Lilly And Company
• AstraZeneca PLC
• Teva Pharmaceuticals Industries Ltd.
• Novartis AG
• Pfizer, Inc.
• Sanofi S.A.
• GlaxoSmithKline PLC
• Takeda Pharmaceutical Company Limited
• Lonza Group AG
• Amgen, Inc.

Unique Offerings from the Publisher

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free